Document Type
Article
Publication Date
September 2021
Patent Number
11123435
Abstract
Disclosed are compositions and methods for targeted treatment of cancers, such as TLR9-expressing cancers. In particular, molecules containing a TLR9 targeting ligand, such as a CpG oligodeoxynucleotide, that target lytic peptides to TLR9-expressing malignant cells are disclosed.
Application Number
16/319935
Recommended Citation
List, Alan; Wei, Sheng; and McLaughlin, Mark L., "TLR9 targeted therapeutics" (2021). USF Patents. 1262.
https://digitalcommons.usf.edu/usf_patents/1262
Assignees
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Filing Date
08/02/2017
COinS
